Clinical trial Recruiting at 2 sites Interventional Ages 8 to 65

Program to help families manage diabetes distress in children

Official title: Remedy to Diabetes Distress (R2D2): A Scalable Screen to Treat Program for School-age Families

Run by Nemours Children's Clinic · NCT05268250 · Data updated 2026-11-12

This study is testing a new program to help families of school-age children with Type 1 Diabetes manage stress related to the condition and see if it improves their health.

More Type 1 Diabetes trials

Quick facts

Study typeInterventional
Ages8 Years to 65 Years
SexAll
Enrollment180 (estimated)
SponsorNemours Children's Clinic
Academic / other
Locations2 sites (Jacksonville, Florida and 1 other locations)
StatusRecruiting
StartedFebruary 26, 2024
Main results expectedAugust 31, 2027
Study endsAugust 31, 2027
Registry record updatedSeptember 1, 2026
Trial IDNCT05268250 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are children aged 8-12 years with a physician-confirmed diagnosis of Type 1 Diabetes who experience diabetes distress.

Probably not a fit

Patients who are on a conventional insulin regimen or do not report diabetes distress levels at or above clinical cut-points may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This project aims to evaluate a new program called Remedy to Diabetes Distress (R2D2) designed to help families of school-age children with Type 1 Diabetes (T1D) manage diabetes distress. The program will assess the feasibility and acceptability of a mobile health intervention that targets both children and their parents, focusing on reducing diabetes distress to improve glycemic control. By addressing the emotional and psychological challenges associated with T1D, the study seeks to enhance the overall management of the condition in young patients. The initial efficacy of the R2D2 program will also be tested to determine its impact on children's health outcomes.

Why it matters

Potential benefit: If successful, this program could significantly improve the emotional well-being of families and enhance glycemic control in children with Type 1 Diabetes.

How similar studies have gone: While there is ongoing research into diabetes distress, this specific approach with a scalable program for families is novel and has not been extensively tested.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* child age between 8-12 years, physician confirmed T1D diagnosis,
* either the child or the parent or both the child and parent report diabetes distress levels at or above clinical cut-points,
* child is on an intensive insulin regimen (pump or MDI).

Exclusion Criteria:

* children on a conventional insulin regimen, children and/or parents who do not report diabetes distress levels at or above the clinical cut-points,
* children who have an allergy or sensitivity to the adhesive and/or skin preparation used for CGM, children with a comorbid chronic condition (e.g., renal disease),
* children and parents who do not speak English.

Where it's running

  • Nemours Children's Health
    Jacksonville, Florida, United States
    Recruiting
  • Children's Mercy Kansas City
    Kansas City, Missouri, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.